Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J Clin. 2024;74(3):229–63. https://doi.org/10.3322/caac.21834.

Article  PubMed  Google Scholar 

Zheng RS, Chen R, Han BF, et al. Cancer incidence and mortality in China, 2022. Zhonghua Zhong Liu Za Zhi. 2024;46(3):221–31. https://doi.org/10.3760/cma.j.cn112152-20240119-00035.

Article  CAS  PubMed  Google Scholar 

Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. CA: Cancer J Clin. 2022;72(1):7–33. https://doi.org/10.3322/caac.21708.

Article  PubMed  Google Scholar 

Rudin CM, Brambilla E, Faivre-Finn C, et al. Small-cell lung cancer. Nat Rev Dis Prim. 2021;7(1):3. https://doi.org/10.1038/s41572-020-00235-0.

Article  PubMed  Google Scholar 

Byers LA, Rudin CM. Small cell lung cancer: where do we go from here? Cancer. 2014;121(5):664–72. https://doi.org/10.1002/cncr.29098.

Article  CAS  PubMed  Google Scholar 

Farago AF, Keane FK. Current standards for clinical management of small cell lung cancer. Transl Lung Cancer Res. 2018;7(1):69–79. https://doi.org/10.21037/tlcr.2018.01.16.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Horn L, Mansfield AS, Szczęsna A, et al. First-line Atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379(23):2220–9. https://doi.org/10.1056/NEJMoa1809064.

Article  CAS  PubMed  Google Scholar 

Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. The Lancet. 2019;394(10212):1929–39. https://doi.org/10.1016/s0140-6736(19)32222-6.

Article  CAS  Google Scholar 

Wang J, Zhou C, Yao W, et al. Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23(6):739–47. https://doi.org/10.1016/s1470-2045(22)00224-8.

Article  CAS  PubMed  Google Scholar 

Cheng Y, Han L, Wu L, et al. Effect of first-line serplulimab vs placebo added to chemotherapy on survival in patients with extensive-stage small cell lung cancer. JAMA. 2022. https://doi.org/10.1001/jama.2022.16464.

Article  PubMed  PubMed Central  Google Scholar 

Cheng Y, Chen J, Zhang W, et al. Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: a randomized phase 3 trial. Nat Med. 2024;30(10):2967–76. https://doi.org/10.1038/s41591-024-03132-1.

Article  CAS  PubMed  PubMed Central  Google Scholar 

[China clinical practice guideline for stage IV primary lung cancer (2024 edition)]. Zhonghua Zhong Liu Za Zhi. 2024;46(7):595–636. https://doi.org/10.3760/cma.j.cn112152-20240311-00104.

You M, Luo L, Lu T, et al. Cost-effectiveness analysis of benmelstobart, anlotinib, and chemotherapy in extensive-stage small-cell lung cancer. Front Immunol. 2024. https://doi.org/10.3389/fimmu.2024.1477146.

Article  PubMed  PubMed Central  Google Scholar 

You C, Zhang J, Lei J, et al. Cost-effectiveness analysis of anlotinib plus chemotherapy with or without benmelstobart versus chemotherapy alone for extensive-stage small-cell lung cancer in China. Front Oncol. 2024. https://doi.org/10.3389/fonc.2024.1484650.

Article  PubMed  PubMed Central  Google Scholar 

Chinese Society of Clinical Oncology. Beijing Xisike Clinical Oncology Research Foundation. http://www.csco.ac.cn/. Accessed 21 Dec 2024.

National Comprehensive Cancer Network. Guidelines-Treatment by Cancer Type. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1462. Accessed 21 Dec 2024.

Ishak KJ, Kreif N, Benedict A, et al. Overview of parametric survival analysis for health-economic applications. Pharmacoeconomics. 2013;31(8):663–75. https://doi.org/10.1007/s40273-013-0064-3.

Article  PubMed  Google Scholar 

Su D, Wu B, Shi L. Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as first-line treatment of unresectable hepatocellular carcinoma. JAMA Netw Open. 2021. https://doi.org/10.1001/jamanetworkopen.2021.0037.

Article  PubMed  PubMed Central  Google Scholar 

Statistical Communiqué of the People's Republic of China on the 2024 National Economic and Social Development. https://data.stats.gov.cn/english/easyquery.htm?cn=C01. Accessed 20 May 2025.

Rossi R, Murari A, Gaudio P, et al. Upgrading Model Selection Criteria with Goodness of Fit Tests for Practical Applications. Entropy. 2020;22(4):447. https://doi.org/10.3390/e22040447.

Article  PubMed  PubMed Central  Google Scholar 

Chinese Pharmaceutical Association. Chinese Pharmacoeconomic Evaluation Guidelines (2020). https://www.cpa.org.cn/cpadmn/attached/file/20201203/1606977380634185.pdf. Accessed 21 Jan 2025

2024 US Dollar (USD) to Chinese Yuan (CNY) Historical Exchange Rates. https://www.exchange-rates.org/zh/exchange-rate-history/usd-cny-2024. Accessed 9 Nov 2024

Guyot P, Ades AE, Ouwens MJ, et al. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan–Meier survival curves. BMC Med Res Methodol. 2012;12:9. https://doi.org/10.1186/1471-2288-12-9.

Article  PubMed  PubMed Central  Google Scholar 

Shao T, Zhao M, Liang L, et al. Impact of extrapolation model choices on the structural uncertainty in economic evaluations for cancer immunotherapy: a case study of Checkmate 067. PharmacoEconomics Open. 2023;7(3):383–92. https://doi.org/10.1007/s41669-023-00391-5.

Article  PubMed  PubMed Central  Google Scholar 

Royston P, Parmar MKB. Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects. Stat Med. 2002;21(15):2175–97. https://doi.org/10.1002/sim.1203.

Article  PubMed  Google Scholar 

Data.CMs.gov. Centers for Medicare & Medicaid Services. https://www.cms.gov/medicare/payment/fee-schedules. Accessed 24 Dec 2024.

Lang W, Ai Q, He Y, et al. Cost-effectiveness analysis of tislelizumab plus chemotherapy versus standard chemotherapy in first-line treatment for extensive-stage small cell lung cancer: perspectives from the United States and China. Int J Clin Pharm. 2024;46(6):1536–45. https://doi.org/10.1007/s11096-024-01802-1.

Article  CAS  PubMed  Google Scholar 

Shao T, Zhao M, Liang L, et al. Serplulimab Plus Chemotherapy vs Chemotherapy for Treatment of US and Chinese Patients with extensive-stage small-cell lung cancer: a cost-effectiveness analysis to inform drug pricing. BioDrugs. 2023;37(3):421–32. https://doi.org/10.1007/s40259-023-00586-6.

Article  CAS  PubMed  Google Scholar 

Sun Y, Xu K, Yao H, et al. Cost-effectiveness of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a comparative analysis in China, the United States and Europe. Int J Clin Pharm. 2024;47(1):196–209. https://doi.org/10.1007/s11096-024-01824-9.

Article  PubMed  Google Scholar 

Wei J, Xu K, Lin Y, et al. Economic evaluation of camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma in the United States and China. Int J Clin Pharm. 2024;46(5):1189–99. https://doi.org/10.1007/s11096-024-01752-8.

Article  PubMed  Google Scholar 

Xiang G, Huang Y, Gan L, et al. Cost-effectiveness of nivolumab plus gemcitabine-cisplatin as first-line treatment for advanced urothelial carcinoma in China and the United States. Front Immunol. 2024;15:1426024. https://doi.org/10.3389/fimmu.2024.1426024.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shen G, Zheng F, Ren D, et al. Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. J Hematol Oncol. 2018;11(1):20. https://doi.org/10.1186/s13045-018-0664-7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Goldstein DA, Chen Q, Ayer T, et al. First- and second-line bevacizumab in addition to chemotherapy for metastatic colorectal cancer: a united states-based cost-effectiveness analysis. J Clin Oncol. 2015;33(10):1112–8. https://doi.org/10.1200/jco.2014.58.4904.

Article  PubMed  PubMed Central  Google Scholar